These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433 [TBL] [Abstract][Full Text] [Related]
24. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia]. Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062 [TBL] [Abstract][Full Text] [Related]
25. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma]. Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752 [TBL] [Abstract][Full Text] [Related]
26. Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF. Jindra P; Koza V; Lysák D; Vozobulová V; Steinerová K Bone Marrow Transplant; 2005 Apr; 35(7):729-30. PubMed ID: 15785772 [No Abstract] [Full Text] [Related]
27. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212 [TBL] [Abstract][Full Text] [Related]
28. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718 [TBL] [Abstract][Full Text] [Related]
29. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948 [TBL] [Abstract][Full Text] [Related]
30. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558 [TBL] [Abstract][Full Text] [Related]
31. [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies]. Qiu HY; Wu DP; Sun AN; Chang WR; Jin ZM; Miao M; Tang XW; Shen YM; Fu ZZ Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):462-5. PubMed ID: 15555260 [TBL] [Abstract][Full Text] [Related]
32. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877 [TBL] [Abstract][Full Text] [Related]
33. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
34. Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. Aulitzky WE; Neubauer A; Kolbe K; Schneller F; Busemann C; Schleiermacher E; Peschel C; Siegert W; Huber C; Huhn D Bone Marrow Transplant; 1996 May; 17 Suppl 3():S67-9. PubMed ID: 8769707 [TBL] [Abstract][Full Text] [Related]
35. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594 [TBL] [Abstract][Full Text] [Related]
36. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592 [TBL] [Abstract][Full Text] [Related]
37. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611 [TBL] [Abstract][Full Text] [Related]
38. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353 [TBL] [Abstract][Full Text] [Related]
39. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related]
40. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]